

PTO/SB/00A (10-01)
Approved for use through 10/31/2002. OM 3 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/752,639
		Filing Date	December 29, 2000
		First Named Inventor	GATANAGA TETSUYA
		Group Art Unit	1646
		Examiner Name	MURPHY, JOSEPH E.
		Attorney Docket Number	IRVN-007CON2
Sheet	2 of 2 (use as many sheets as necessary)		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cita No. ¹	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Aderka et al. "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients." Cancer Res. 51:5602, 1991.
		Aggarwal et al. "Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon." Nature 318:665, 1985.
		Baglioni et al. "Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition." J. Biol. Chem. 260:13395, 1985.
		Brakebusch et al. "Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signaling, but not induced shedding of the receptor." EMBO J. 11:943, 1992.
		Diez-Ruiz et al. "Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis." Eur. J. Haematol. 54:1, 1995.
		Grosen et al. "Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy." Gynecol. Oncol. 50:68, 1993.
		Gullberg et al. "Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain." Eur. J. Cell Biol. 58:307, 1992.
		Halwachs et al. "Serum levels of the soluble receptor for tumor necrosis factor in patients with renal disease." Clin. Invest. 72:473, 1994.
		Holtmann & Wallach. "Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate." J. Immunol. 139:1161, 1987.
		Kochi et al. "Characterization and affinity crosslinking of receptors for tumor necrosis factor on human cells." Arch. Biochem. Biophys. 249:263, 1986.
		Kull et al. "Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity." Proc. Natl. Acad. Sci. USA 82:5756, 1985.
		Porteu et al. "Shedding of tumor necrosis factor receptors by activated human neutrophils." J. Exp. Med. 172:599, 1990.
		Redl et al. "Tumor necrosis factor (TNF) dependent shedding of the p55 TNF receptor in a baboon model of bacteremia." Infect. Immun. 63:297, 1995.
		Schall et al. "Molecular cloning and expression of a receptor for human tumor necrosis factor." [Relation between membrane TNF-R and the soluble form] Cell 61:361, 1990.
Examiner Signature		
Date Considered	8-26-02	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/752,639
		Filing Date	December 29, 2000
		First Named Inventor	GATANAGA, TETSUYA
		Art Unit	1646
		Examiner Name	MURPHY, JOSEPH E.
Sheet 1 of 1	Attorney Docket Number	IRVN-007CON2	

Examiner Initials ¹	Cito No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US-	5,945,397	August 31, 1999	Smith et al.	
		US-	6,413,741	July 2, 2002	Jegla et al.	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

Examiner Initials ¹	Cito No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7 ⁶
		Country Code ² -Number ³ -Kind Code ⁴ (if known)					
		PCT	WO 98/20140	05-14-1998	Granger et al.		

Examiner Signature		Date Considered	8-26-03
-----------------------	--	--------------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SD/08A (10-01)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/752,639
		Filing Date	December 29, 2000
		First Named Inventor	GATANAGA, JETSUYA
		Group Art Unit	1646
		Examiner Name	MURPHY, JOSEPH E.
Sheet 2 of 2	Attorney Docket Number	IRVN-007CON2	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
J		Yonchara et al. "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor." J. Exp. Med. 169:1747, 1989.
X		Yoshie et al. "Binding and crosslinking of 125I-labeled recombinant human tumor necrosis factor to cell surface receptors. J. Biochem. (Tokyo) 100:531, 1986.
Examiner Signature		Date Considered 8-26-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.